Back

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

2023-12-18 rheumatology Title + abstract only
View on medRxiv
Show abstract

BackgroundSulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one year. To rationalise monitoring we developed and validated a prognostic model for clinically significant blood, liver, or kidney toxicity during established sulfasalazine treatment. DesignRetrospective cohort study. SettingUK primary-care. Data from C...

Predicted journal destinations